GlassScriptPhysician profile
Michael B Bagwell
NPI 1558306019
$12,737.54
in general payments reported to CMS, 2019-2025
36 companies · $1,673 in 2025
The $1,673 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,281 · 2020: $1,380 · 2021: $1,926 · 2022: $2,509 · 2023: $1,907 · 2024: $2,061 · 2025: $1,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,629 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,629.43 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,606.39 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,460.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,277.66 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $840.47 | 2019-2024 | Jardiance |
| Abbvie INC. | $829.60 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Janssen Pharmaceuticals, INC | $799.37 | 2019-2025 | Xarelto, Spravato |
| Glaxosmithkline, LLC. | $715.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $644.00 | 2019-2023 | |
| Amgen INC. | $615.13 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $603.24 | 2021-2025 | |
| Pfizer INC. | $528.92 | 2019-2025 | |
| Dexcom, INC. | $313.75 | 2021-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $313.09 | 2020-2025 | Nexletol, Nexlizet |
| Abbott Laboratories | $303.52 | 2023-2025 | Freestyle Libre 3, Cell-Dyn |
| Takeda Pharmaceuticals U.S.A., INC. | $219.48 | 2019-2025 | Trintellix |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bagwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.